Citius (CTXR). Dang Flippers!
Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.
2021 and 2020 Milestones In Plain Sight.
Locked and Loaded for most of 2020 - many major milestone...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Immunomedics (IMMU) $3.00 to $88, Up 29-fold, Our Second Best Idea Ever.
Interesting Charts From the Day we Discovered it.
Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced...
Citius Pharmaceuticals, Inc. (CTXR) Reports Fiscal Full Year 2023 Financial Results and Provides Business...
Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024
LYMPHIR™ BLA resubmission on track for early 2024
Make Hay While the Sun Shines. Up 6,400%.
Celcius (CELH) We're Up 6,400%. Alkaline Water (WTER) We're Up 12%.Dicerna (DRNA) We're Up 700%. Ready to Breakout?BioSig (BSGM) We Have...
And We Have Another Double. Frontier Bio (FBIO) Crosses $4.00.
Sometimes we Can't Beleive Our Luck Over the Last Couple Years. But There You Have it, at Least we Know It's...
More Great News From Citius Pharma (CTXR).
UPDATED CHART 6-15-21
Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
2020 Biotech Portfolio Soars 55%, We’re Amazed.
1. Yep, We Are Absolutely Amazed At The Biotech Stock Review’s 2020 Watch List Performance – Especially In The Light Of –...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
